Payment overview · 2025
General Payments
$558.60
25 reported records · 11 companies
Healthcare provider profile · identity verified
John Savage, MD
Allopathic & Osteopathic Physicians|Family Medicine · PERU, IN · NPI 1942265483
Verified facts
What the public records show
CMS Open Payments records show John Savage, MD received $558.60 in general payments during 2025 across 25 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $99.81 | 17.9% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $91.12 | 16.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.13 | 14.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.08 | 10.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.98 | 10.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.89 | 8.8% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $32.49 | 5.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.97 | 5.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.59 | 4.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.37 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.17 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $558.60 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $99.81 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $91.12 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.13 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.13 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $60.08 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.89 | 2 | 2025 |
Source payment records
|
|||||
| PICO Normalized: pico |
Device | Smith+Nephew, Inc. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 67 |
| Omeprazole | Omeprazole | 361 | 75 |
| Lisinopril | Lisinopril | 349 | 92 |
| Metformin Hcl | Metformin Hcl | 281 | 63 |
| Gabapentin | Gabapentin | 256 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 54 |
| Eliquis | Apixaban | 219 | 23 |
| Losartan Potassium | Losartan Potassium | 194 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 57 |
| Carvedilol | Carvedilol | 162 | 32 |
| Furosemide | Furosemide | 157 | 40 |
| Meloxicam | Meloxicam | 157 | 32 |
| Allopurinol | Allopurinol | 153 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 34 |
| Trazodone Hcl | Trazodone Hcl | 147 | 32 |
| Sertraline Hcl | Sertraline Hcl | 142 | 27 |
| Famotidine | Famotidine | 136 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 32 |
| Potassium Chloride | Potassium Chloride | 124 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 32 |
| Buspirone Hcl | Buspirone Hcl | 120 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 117 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 30 |
| Montelukast Sodium | Montelukast Sodium | 114 | 18 |
| Trulicity | Dulaglutide | 109 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 20 |
| Haloperidol | Haloperidol | 98 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 13 |
| Ozempic | Semaglutide | 95 | 12 |
| Donepezil Hcl | Donepezil Hcl | 93 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 80 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 22 |
| Topiramate | Topiramate | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 14 |
| Jardiance | Empagliflozin | 65 | 12 |
| Spironolactone | Spironolactone | 65 | 16 |
| Chlorthalidone | Chlorthalidone | 64 | 19 |
| Tramadol Hcl | Tramadol Hcl | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 16 |
| Cephalexin | Cephalexin | 59 | 38 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Risperidone | Risperidone | 56 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Lorazepam | Lorazepam | 54 | 11 |
| Simvastatin | Simvastatin | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | suppressed |
| Alprazolam | Alprazolam | 51 | 13 |
| Baclofen | Baclofen | 51 | 11 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 31 |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Scopolamine | Scopolamine | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 15 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 26 |
| Azithromycin | Azithromycin | 35 | 29 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 14 |
| Nystatin | Nystatin | 33 | 19 |
| Mounjaro | Tirzepatide | 32 | 11 |
| Prednisone | Prednisone | 32 | 18 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Glipizide | Glipizide | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 21 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Austedo | Deutetrabenazine | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Tetrabenazine | Tetrabenazine | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Estradiol | Estradiol | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Yuvafem | Estradiol | 13 | suppressed |
| Alprazolam Odt | Alprazolam | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | 11 |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $558.60 · 25 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, CAPLYTA, Dexcom G6 Transmitter, INGREZZA, MAVYRET, MOUNJARO, OTEZLA, Ozempic, PICO, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error